Cargando…
A Qualitative Comparison of the Abbott SARS-CoV-2 IgG II Quant Assay against Commonly Used Canadian SARS-CoV-2 Enzyme Immunoassays in Blood Donor Retention Specimens, April 2020 to March 2021
Our group has previously used laboratory and commercially developed assays to understand the IgG responses to SARS-CoV-2 antigens, including nucleocapsid (N), spike (S), and receptor binding domain (RBD), in Canadian blood donors. In this current study, we analyzed 17,428 available and previously ch...
Autores principales: | Abe, Kento T., Rathod, Bhavisha, Colwill, Karen, Gingras, Anne-Claude, Tuite, Ashleigh, Robbins, Ninette F., Orjuela, Guillermo, Jenkins, Craig, Conrod, Valerie, Yi, Qi-Long, O’Brien, Sheila F., Drews, Steven J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241784/ https://www.ncbi.nlm.nih.gov/pubmed/35652636 http://dx.doi.org/10.1128/spectrum.01134-22 |
Ejemplares similares
-
Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses
por: Lin, Yi-Chan J., et al.
Publicado: (2022) -
Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021
por: Lin, Yi-Chan J., et al.
Publicado: (2023) -
Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays
por: Tuite, Ashleigh R., et al.
Publicado: (2022) -
SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History
por: Drews, Steven J., et al.
Publicado: (2022) -
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard
por: Saeed, Sahar, et al.
Publicado: (2021)